{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T23:09:06Z","timestamp":1789168146176,"version":"build-2803163510"},"reference-count":24,"publisher":"Oxford University Press (OUP)","issue":"7","license":[{"start":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T00:00:00Z","timestamp":1783555200000},"content-version":"vor","delay-in-days":8,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100007234","name":"University of Chicago","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007234","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Primary Care Investigators Training in Chronic Disease and Health Disparities"},{"DOI":"10.13039\/100000102","name":"Health Resources and Services Administration","doi-asserted-by":"publisher","award":["T32 HP42019"],"award-info":[{"award-number":["T32 HP42019"]}],"id":[{"id":"10.13039\/100000102","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,7,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Lenacapavir (LEN), a first-in-class long-acting human immunodeficiency virus type 1 (HIV-1) capsid inhibitor, has demonstrated potent antiviral activity in heavily treatment-experienced (HTE) people with HIV (PWH) in clinical trials, but real-world data remain limited. We describe outcomes from 6 US HIV clinics using LEN-based regimens in a largely HTE cohort of PWH to assess virologic response, regimen potency, and tolerability.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a multicenter retrospective cohort study of adults with HIV who initiated LEN between November 2020 and June 2025 at 6 clinics in Chicago, Illinois and Pittsburgh, Pennsylvania. Demographic, clinical, and genotypic data were abstracted from electronic health records. Virologic suppression was defined as HIV viral load &amp;lt;200\u2005copies\/mL. Stanford genotypic susceptibility scores (S-GSS) were calculated to assess regimen potency. Wilcoxon signed-rank tests compared antiretroviral therapy pill burden and regimen potency before and after LEN initiation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Seventy PWH initiated LEN. Median follow-up was 12 months. At baseline, 18 (26%) PWH with available genotypes had multidrug-resistant HIV, and 54% had unsuppressed virus. Among 38 PWH with unsuppressed virus, 34 (89%) achieved viral suppression, and none of the PWH with suppressed HIV experienced rebound. LEN significantly improved regimen potency (P &amp;lt; .00005) and reduced daily pill burden from 2 tablets to 1 tablet (P &amp;lt; .00005). Injection site reactions occurred in 30% and led to discontinuation in 1 person.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In this real-world cohort, LEN-based regimens achieved high rates of virologic suppression, improved regimen activity, and reduced pill burden with good tolerability. LEN represents a promising salvage therapy for PWH, warranting equitable and implementation-focused integration into HIV care.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ofid\/ofag425","type":"journal-article","created":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T11:47:40Z","timestamp":1783424860000},"source":"Crossref","is-referenced-by-count":1,"title":["Virologic Outcomes With Lenacapavir in People With Human Immunodeficiency Virus: A Multicenter Real-World Study"],"prefix":"10.1093","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-8233-3091","authenticated-orcid":false,"given":"Christopher","family":"Kaperak","sequence":"first","affiliation":[{"name":"Department of Medicine, Section of Infectious Diseases and Global Health, University of Chicago Medicine , Chicago, Illinois ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5300-0571","authenticated-orcid":false,"given":"Yijia","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Infectious Diseases, University of Pittsburgh , Pittsburgh, Pennsylvania ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9659-3554","authenticated-orcid":false,"given":"Beverly","family":"Sha","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Division of Infectious Diseases, Rush University Medical Center , Chicago, Illinois ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica","family":"Mercon","sequence":"additional","affiliation":[{"name":"Ruth M. Rothstein CORE Center, Cook County Health , Chicago, Illinois ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Montes","sequence":"additional","affiliation":[{"name":"Ruth M. Rothstein CORE Center, Cook County Health , Chicago, Illinois ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4046-9594","authenticated-orcid":false,"given":"Maria","family":"Sanes Guevara","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Infectious Diseases, University of Pittsburgh , Pittsburgh, Pennsylvania ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0911-7438","authenticated-orcid":false,"given":"Shivanjali","family":"Shankaran","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Division of Infectious Diseases, Rush University Medical Center , Chicago, Illinois ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariam","family":"Aziz","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Division of Infectious Diseases, Rush University Medical Center , Chicago, Illinois ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Creticos","sequence":"additional","affiliation":[{"name":"Howard Brown Health , Chicago, Illinois ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nancy","family":"Glick","sequence":"additional","affiliation":[{"name":"Sinai Infectious Disease Center, Sinai Chicago , Chicago, Illinois ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bijou R","family":"Hunt","sequence":"additional","affiliation":[{"name":"Sinai Infectious Disease Center, Sinai Chicago , Chicago, Illinois ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-5234-0310","authenticated-orcid":false,"given":"Sharon","family":"Sam","sequence":"additional","affiliation":[{"name":"Sinai Infectious Disease Center, Sinai Chicago , Chicago, Illinois ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Djuricich","sequence":"additional","affiliation":[{"name":"Department of Medicine, Section of Infectious Diseases and Global Health, University of Chicago Medicine , Chicago, Illinois ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Merker","sequence":"additional","affiliation":[{"name":"Department of Medicine, Section of Infectious Diseases and Global Health, University of Chicago Medicine , Chicago, Illinois ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8557-4465","authenticated-orcid":false,"given":"Aniruddha","family":"Hazra","sequence":"additional","affiliation":[{"name":"Department of Medicine, Section of Infectious Diseases and Global Health, University of Chicago Medicine , Chicago, Illinois ,","place":["USA"]},{"name":"Howard Brown Health , Chicago, Illinois ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,7,9]]},"reference":[{"key":"2026072106162458700_ofag425-B1","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1007\/s40265-022-01786-0","article-title":"Lenacapavir: first approval","volume":"82","author":"Paik","year":"2022","journal-title":"Drugs"},{"key":"2026072106162458700_ofag425-B2","author":"Gilead Sciences"},{"key":"2026072106162458700_ofag425-B3","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1056\/NEJMoa2115542","article-title":"Capsid inhibition with lenacapavir in multidrug-resistant HIV-1 infection","volume":"386","author":"Segal-Maurer","year":"2022","journal-title":"N Engl J Med"},{"key":"2026072106162458700_ofag425-B4","doi-asserted-by":"crossref","first-page":"e15","DOI":"10.1016\/S2352-3018(22)00291-0","article-title":"Lenacapavir administered every 26 weeks or daily in combination with oral daily antiretroviral therapy for initial treatment of HIV: a randomised, open-label, active-controlled, phase 2 trial","volume":"10","author":"Gupta","year":"2023","journal-title":"Lancet HIV"},{"key":"2026072106162458700_ofag425-B5","doi-asserted-by":"crossref","first-page":"ofaf615","DOI":"10.1093\/ofid\/ofaf615","article-title":"Efficacy and safety of bictegravir plus lenacapavir: 48-week outcomes in people with HIV-1 who are virologically suppressed on complex antiretroviral regimens at baseline","volume":"12","author":"Mounzer","year":"2025","journal-title":"Open Forum Infect Dis"},{"key":"2026072106162458700_ofag425-B6","doi-asserted-by":"crossref","first-page":"168","DOI":"10.7326\/ANNALS-25-01939","article-title":"Once-weekly oral islatravir plus lenacapavir versus daily oral bictegravir, emtricitabine, and tenofovir alafenamide in persons with HIV-1","volume":"179","author":"Colson","year":"2026","journal-title":"Ann Intern Med"},{"key":"2026072106162458700_ofag425-B7","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1056\/NEJMoa2407001","article-title":"Twice-yearly lenacapavir or daily F\/TAF for HIV prevention in cisgender women","volume":"391","author":"Bekker","year":"2024","journal-title":"N Engl J Med"},{"key":"2026072106162458700_ofag425-B8","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1056\/NEJMoa2411858","article-title":"Twice-yearly lenacapavir for HIV prevention in men and gender-diverse persons","volume":"392","author":"Kelley","year":"2025","journal-title":"N Engl J Med"},{"key":"2026072106162458700_ofag425-B9","doi-asserted-by":"crossref","first-page":"e500","DOI":"10.1016\/S1473-3099(25)00490-6","article-title":"New lenacapavir guidelines from WHO","volume":"25","author":"Kirby","year":"2025","journal-title":"Lancet Infect Dis"},{"key":"2026072106162458700_ofag425-B10","author":"Gilead Sciences"},{"key":"2026072106162458700_ofag425-B11","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1093\/cid\/ciae423","article-title":"Efficacy and safety of long-acting subcutaneous lenacapavir in heavily treatment-experienced people with multidrug-resistant HIV-1: week 104 results of a phase 2\/3 trial","volume":"80","author":"Ogbuagu","year":"2025","journal-title":"Clin Infect Dis"},{"key":"2026072106162458700_ofag425-B12","doi-asserted-by":"publisher","author":"Mounzer","DOI":"10.1093\/ofid\/ofaf695.128"},{"key":"2026072106162458700_ofag425-B13","doi-asserted-by":"crossref","first-page":"ofaf651","DOI":"10.1093\/ofid\/ofaf651","article-title":"Lenacapavir plus cabotegravir as combination treatment: real-world use cases from the National Clinician Consultation Center","volume":"12","author":"Saberi","year":"2025","journal-title":"Open Forum Infect Dis"},{"key":"2026072106162458700_ofag425-B14","author":"Kaperak"},{"key":"2026072106162458700_ofag425-B15","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1186\/s12879-023-08038-w","article-title":"Heavily treatment-experienced people living with HIV in the OPERA\u00ae cohort: population characteristics and clinical outcomes","volume":"23","author":"Hsu","year":"2023","journal-title":"BMC Infect Dis"},{"key":"2026072106162458700_ofag425-B16"},{"key":"2026072106162458700_ofag425-B17","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1159\/000331998","article-title":"The HIVdb system for HIV-1 genotypic resistance interpretation","volume":"55","author":"Tang","year":"2012","journal-title":"Intervirology"},{"key":"2026072106162458700_ofag425-B18","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1111\/hiv.70092","article-title":"Natural occurrence of drug resistance mutations to the HIV-1 capsid inhibitor lenacapavir","volume":"26","author":"Weibull W\u00e4rnberg","year":"2025","journal-title":"HIV Med"},{"issue":"Suppl 1","key":"2026072106162458700_ofag425-B19","doi-asserted-by":"crossref","first-page":"ofae631.041","DOI":"10.1093\/ofid\/ofae631.041","article-title":"155. Long-acting subcutaneous lenacapavir in people with multi-drug resistant HIV-1: 3-year results of the CAPELLA study","volume":"12","author":"Ogbuagu","year":"2025","journal-title":"Open Forum Infect Dis"},{"key":"2026072106162458700_ofag425-B20","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1093\/cid\/ciu046","article-title":"Lower pill burden and once-daily antiretroviral treatment regimens for HIV infection: a meta-analysis of randomized controlled trials","volume":"58","author":"Nachega","year":"2014","journal-title":"Clin Infect Dis"},{"key":"2026072106162458700_ofag425-B21","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1310\/hct1501-14","article-title":"Minorities remain underrepresented in HIV\/AIDS research despite access to clinical trials","volume":"15","author":"Castillo-Mancilla","year":"2014","journal-title":"HIV Clin Trials"},{"key":"2026072106162458700_ofag425-B22","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1097\/JNC.0000000000000224","article-title":"Documenting successes 30 years after passage of the Ryan White CARE Act","volume":"32","author":"Weiser","year":"2021","journal-title":"J Assoc Nurses AIDS Care"},{"key":"2026072106162458700_ofag425-B23","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1093\/infdis\/jiaf050","article-title":"Resistance analyses in heavily treatment-experienced people with HIV treated with the novel HIV capsid inhibitor lenacapavir after 2 years","volume":"231","author":"Margot","year":"2025","journal-title":"J Infect Dis"},{"key":"2026072106162458700_ofag425-B24","doi-asserted-by":"crossref","first-page":"e732","DOI":"10.1016\/S2352-3018(25)00128-6","article-title":"Lenacapavir-associated drug resistance: implications for scaling up long-acting HIV pre-exposure prophylaxis","volume":"12","author":"van Zyl","year":"2025","journal-title":"Lancet HIV"}],"container-title":["Open Forum Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ofid\/advance-article-pdf\/doi\/10.1093\/ofid\/ofag425\/68738795\/ofag425.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ofid\/article-pdf\/13\/7\/ofag425\/68738795\/ofag425.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ofid\/article-pdf\/13\/7\/ofag425\/68738795\/ofag425.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T10:16:33Z","timestamp":1784628993000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ofid\/article\/doi\/10.1093\/ofid\/ofag425\/8729082"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,1]]},"references-count":24,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ofid\/ofag425","relation":{},"ISSN":["2328-8957"],"issn-type":[{"value":"2328-8957","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,7]]},"published":{"date-parts":[[2026,7,1]]},"article-number":"ofag425"}}